Humoral vaccine responses following Chimeric Antigen Receptor T-cell therapy for hematological malignancies - Quiz - MDSpire

Humoral vaccine responses following Chimeric Antigen Receptor T-cell therapy for hematological malignancies

  • By

  • Sigrun Einarsdottir

  • Stephanie Lobaugh

  • Danny Luan

  • Marina Gomez-Llobell

  • Padmapriya Subramanian

  • Sean Devlin

  • David Chung

  • Parastoo B. Dahi

  • Lorenzo Falchi

  • Sergio Giralt

  • Heather Landau

  • Alexander M. Lesokhin

  • Richard Lin

  • Jennifer Lue

  • Sham Mailankody

  • M. Lia Palomba

  • Jae H. Park

  • Gilles Salles

  • Michael Scordo

  • Silvia Escribano-Serrat

  • Jaime Sanz

  • Kai Rejeski

  • Roni Shouval

  • Saad Usmani

  • Miguel-Angel Perales

  • Gunjan Shah

  • Zainab Shahid

  • July 2, 2025

  • 0 min

Share

Original Source(s)

Humoral vaccine responses following Chimeric Antigen Receptor T-cell therapy for hematological malignancies

  • by Sigrun Einarsdottir, Stephanie Lobaugh, Danny Luan, Marina Gomez-Llobell, Padmapriya Subramanian, Sean Devlin, David Chung, Parastoo B. Dahi, Lorenzo Falchi, Sergio Giralt, Heather Landau, Alexander M. Lesokhin, Richard Lin, Jennifer Lue, Sham Mailankody, M. Lia Palomba, Jae H. Park, Gilles Salles, Michael Scordo, Silvia Escribano-Serrat, Jaime Sanz, Kai Rejeski, Roni Shouval, Saad Usmani, Miguel-Angel Perales, Gunjan Shah, Zainab Shahid

  • July 2, 2025

Related Content

Humoral and cellular immunity to SARS-CoV-2 Ancestral and Omicron BA.5 variants following vaccination in myelofibrosis patients

A Chlamydia trachomatis CPAF-STING agonist conjugate vaccine administered intramuscularly and intradermally is immunogenic in the pig model

Viral infections and risk, in Wine and Medicine